Psyence BioMed (Nasdaq: PBM) announced that its strategic partner, PsyLabs, has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract meeting food-grade consumption safety standards. This achievement follows PBM’s strategic equity investments in PsyLabs during 2024 and 2025.
The breakthrough represents a significant milestone in producing high-quality psychedelic APIs, with PsyLabs’ extract passing third-party laboratory verification. ...
